Prognostic factors for treatment outcome in advanced non-small-cell lung cancer (NSCLC): retrospective study and preliminary results

被引：0
|
作者：
Grigorescu, AC [1 ]
Dinu, B [1 ]
Boldeanu, C [1 ]
机构：
[1] Inst Oncol Bucharest, Bucharest, Romania
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：307 / 308
页数：2
相关论文
共 50 条
  • [21] Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC)
    Carcereny Costa, Enric
    Vinolas Segarra, Nuria
    Gascon Vilaplana, Pere
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (04): : 198 - 203
  • [22] Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC)
    Enric Carcereny Costa
    Núria Viñolas Segarra
    Pere Gascón Vilaplana
    [J]. Clinical and Translational Oncology, 2008, 10
  • [23] Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study
    Chen, Xiaofeng
    Zhu, Quan
    Liu, Yiqian
    Liu, Ping
    Yin, Yongmei
    Guo, Renhua
    Lu, Kaihua
    Gu, Yanhong
    Liu, Lianke
    Wang, Jinghua
    Wang, Zhaoxia
    Roe, Oluf Dimitri
    Shu, Yongqian
    Zhu, Lingjun
    [J]. PLOS ONE, 2014, 9 (05):
  • [24] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
  • [25] Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer
    Pujol, JL
    von Pawel, J
    Tumolo, S
    Martoni, A
    Hearn, S
    Fields, SZ
    Ross, G
    [J]. ONCOLOGY, 2001, 61 : 47 - 54
  • [26] Outcome and prognostic factors for patients with non-small-cell lung cancer and severe radiation pneumonitis
    Wang, JY
    Chen, KY
    Wang, JT
    Chen, JH
    Lin, JW
    Wang, HC
    Lee, LN
    Yang, PC
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (03): : 735 - 741
  • [27] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC)
    Grossi, F.
    Brianti, A.
    Defferrari, C.
    Dal Bello, M. G.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 395 - 395
  • [28] Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC)
    Chen, Lian
    Chen, Rui
    Zhu, Zhe
    Zhang, Yichen
    Wen, Zhengwei
    Li, Yun
    Li, Xiaoming
    Luo, Yuwen
    Ma, Liyu
    Lin, Shuguang
    Chen, Xin
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (04) : 466 - 470
  • [29] PREDICTIVE FACTORS ASSOCIATED WITH GEFITINIB RESPONSE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Xu, F.
    Zhou, T.
    Duan, J.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 47 - 47
  • [30] Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC)
    Defferrari, C.
    Brianti, A.
    Dal Bello, M. G.
    Loprevite, M.
    Catania, G.
    Pronzato, P.
    Grossi, F.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 24 - 24
12345